-
1
-
-
0345601083
-
Met, metastasis, motility and more
-
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-25.
-
(2003)
Nat Rev Mol Cell Biol
, vol.4
, pp. 915-925
-
-
Birchmeier, C.1
Birchmeier, W.2
Gherardi, E.3
Vande Woude, G.F.4
-
3
-
-
33846876103
-
Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics
-
Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007; 13:671-9.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 671-679
-
-
Linehan, W.M.1
Pinto, P.A.2
Srinivasan, R.3
Merino, M.4
Choyke, P.5
Choyke, L.6
Coleman, J.7
Toro, J.8
Glenn, G.9
Vocke, C.10
Zbar, B.11
Schmidt, L.S.12
Bottaro, D.13
Neckers, L.14
-
4
-
-
0034673699
-
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
-
Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000; 19:1547-55.
-
(2000)
Oncogene
, vol.19
, pp. 1547-1555
-
-
Di Renzo, M.F.1
Olivero, M.2
Martone, T.3
Maffe, A.4
Maggiora, P.5
Stefani, A.D.6
Valente, G.7
Giordano, S.8
Cortesina, G.9
Comoglio, P.M.10
-
5
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
6
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
7
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
Doherty, J.4
Politi, K.5
Sarkaria, I.6
Singh, B.7
Heelan, R.8
Rusch, V.9
Fulton, L.10
Mardis, E.11
Kupfer, D.12
Wilson, R.13
Kris, M.14
Varmus, H.15
-
8
-
-
0027055114
-
Frequent amplification of the c-met gene in scirrhous type stomach cancer
-
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189:227-32.
-
(1992)
Biochem Biophys Res Commun
, vol.189
, pp. 227-232
-
-
Kuniyasu, H.1
Yasui, W.2
Kitadai, Y.3
Yokozaki, H.4
Ito, H.5
Tahara, E.6
-
9
-
-
0033012995
-
Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization
-
Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, Date K, Hagiwara A, Yamaguchi T, Takahashi T, Nakamura Y, Abe T, Inazawa J. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer 1999; 24:299-305.
-
(1999)
Genes Chromosomes Cancer
, vol.24
, pp. 299-305
-
-
Sakakura, C.1
Mori, T.2
Sakabe, T.3
Ariyama, Y.4
Shinomiya, T.5
Date, K.6
Hagiwara, A.7
Yamaguchi, T.8
Takahashi, T.9
Nakamura, Y.10
Abe, T.11
Inazawa, J.12
-
10
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Park, J.O.6
Lindeman, N.7
Gale, C.M.8
Zhao, X.9
Christensen, J.10
Kosaka, T.11
Holmes, A.J.12
Rogers, A.M.13
Cappuzzo, F.14
Mok, T.15
Lee, C.16
Johnson, B.E.17
Cantley, L.C.18
Janne, P.A.19
-
11
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-7.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
Riely, G.4
Viale, A.5
Wang, L.6
Chitale, D.7
Motoi, N.8
Szoke, J.9
Broderick, S.10
Balak, M.11
Chang, W.C.12
Yu, C.J.13
Gazdar, A.14
Pass, H.15
Rusch, V.16
Gerald, W.17
Huang, S.F.18
Yang, P.C.19
Miller, V.20
Ladanyi, M.21
Yang, C.H.22
Pao, W.23
more..
-
12
-
-
33144462553
-
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
-
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103:2316-21.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 2316-2321
-
-
Smolen, G.A.1
Sordella, R.2
Muir, B.3
Mohapatra, G.4
Barmettler, A.5
Archibald, H.6
Kim, W.J.7
Okimoto, R.A.8
Bell, D.W.9
Sgroi, D.C.10
Christensen, J.G.11
Settleman, J.12
Haber, D.A.13
-
13
-
-
32944467848
-
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
-
Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66:1721-9.
-
(2006)
Cancer Res
, vol.66
, pp. 1721-1729
-
-
Burgess, T.1
Coxon, A.2
Meyer, S.3
Sun, J.4
Rex, K.5
Tsuruda, T.6
Chen, Q.7
Ho, S.Y.8
Li, L.9
Kaufman, S.10
McDorman, K.11
Cattley, R.C.12
Sun, J.13
Elliott, G.14
Zhang, K.15
Feng, X.16
Jia, X.C.17
Green, L.18
Radinsky, R.19
Kendall, R.20
more..
-
14
-
-
0037478437
-
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
-
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-61.
-
(2003)
Cancer Cell
, vol.3
, pp. 347-361
-
-
Pennacchietti, S.1
Michieli, P.2
Galluzzo, M.3
Mazzone, M.4
Giordano, S.5
Comoglio, P.M.6
-
15
-
-
0035845485
-
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase
-
Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Woude GF, Webb CP. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA 2001; 98:10722-7.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 10722-10727
-
-
Furge, K.A.1
Kiewlich, D.2
Le, P.3
Vo, M.N.4
Faure, M.5
Howlett, A.R.6
Lipson, K.E.7
Woude, G.F.8
Webb, C.P.9
-
16
-
-
0031006805
-
Activated ras and ret oncogenes induce overexpression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells
-
Ivan M, Bond JA, Prat M, Comoglio PM, Wynford Thomas D. Activated ras and ret oncogenes induce overexpression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997; 14:2417-23.
-
(1997)
Oncogene
, vol.14
, pp. 2417-2423
-
-
Ivan, M.1
Bond, J.A.2
Prat, M.3
Comoglio, P.M.4
Wynford Thomas, D.5
-
17
-
-
0032558793
-
Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis
-
Webb CP, Taylor GA, Jeffers M, Fiscella M, Oskarsson M, Resau JH, Vande Woude GF. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 1998; 17:2019-25.
-
(1998)
Oncogene
, vol.17
, pp. 2019-2025
-
-
Webb, C.P.1
Taylor, G.A.2
Jeffers, M.3
Fiscella, M.4
Oskarsson, M.5
Resau, J.H.6
Vande Woude, G.F.7
-
18
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-25.
-
(2002)
Cancer Cell
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
Gorre, M.E.4
Paquette, R.L.5
Kuriyan, J.6
Sawyers, C.L.7
-
19
-
-
14944352767
-
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
-
Debiec Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128:270-9.
-
(2005)
Gastroenterology
, vol.128
, pp. 270-279
-
-
Debiec Rychter, M.1
Cools, J.2
Dumez, H.3
Sciot, R.4
Stul, M.5
Mentens, N.6
Vranckx, H.7
Wasag, B.8
Prenen, H.9
Roesel, J.10
Hagemeijer, A.11
Van Oosterom, A.12
Marynen, P.13
-
20
-
-
1042301962
-
Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma
-
Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, Casali PG, Pierotti MA, Pilotti S. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res 2004; 10:938-43.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 938-943
-
-
Tamborini, E.1
Bonadiman, L.2
Greco, A.3
Gronchi, A.4
Riva, C.5
Bertulli, R.6
Casali, P.G.7
Pierotti, M.A.8
Pilotti, S.9
-
21
-
-
33749824425
-
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
-
Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, Greco A, Gronchi A, Casali PG, Ferrone M, Fermeglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 2006; 25:6140-6.
-
(2006)
Oncogene
, vol.25
, pp. 6140-6146
-
-
Tamborini, E.1
Pricl, S.2
Negri, T.3
Lagonigro, M.S.4
Miselli, F.5
Greco, A.6
Gronchi, A.7
Casali, P.G.8
Ferrone, M.9
Fermeglia, M.10
Carbone, A.11
Pierotti, M.A.12
Pilotti, S.13
-
22
-
-
3142676436
-
Overriding imatinib resistance with a novel ABL kinase inhibitor
-
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
-
(2004)
Science
, vol.305
, pp. 399-401
-
-
Shah, N.P.1
Tran, C.2
Lee, F.Y.3
Chen, P.4
Norris, D.5
Sawyers, C.L.6
-
23
-
-
31644438945
-
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680
-
Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006; 66:1007-14.
-
(2006)
Cancer Res
, vol.66
, pp. 1007-1014
-
-
Young, M.A.1
Shah, N.P.2
Chao, L.H.3
Seeliger, M.4
Milanov, Z.V.5
Biggs 3rd, W.H.6
Treiber, D.K.7
Patel, H.K.8
Zarrinkar, P.P.9
Lockhart, D.J.10
Sawyers, C.L.11
Kuriyan, J.12
-
24
-
-
33745283618
-
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
-
Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66:5790-7.
-
(2006)
Cancer Res
, vol.66
, pp. 5790-5797
-
-
Tokarski, J.S.1
Newitt, J.A.2
Chang, C.Y.3
Cheng, J.D.4
Wittekind, M.5
Kiefer, S.E.6
Kish, K.7
Lee, F.Y.8
Borzillerri, R.9
Lombardo, L.J.10
Xie, D.11
Zhang, Y.12
Klei, H.E.13
-
25
-
-
20344393896
-
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
-
Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182-90.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4182-4190
-
-
Antonescu, C.R.1
Besmer, P.2
Guo, T.3
Arkun, K.4
Hom, G.5
Koryotowski, B.6
Leversha, M.A.7
Jeffrey, P.D.8
Desantis, D.9
Singer, S.10
Brennan, M.F.11
Maki, R.G.12
DeMatteo, R.P.13
-
26
-
-
12144291080
-
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
-
Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40:689-95.
-
(2004)
Eur J Cancer
, vol.40
, pp. 689-695
-
-
Debiec-Rychter, M.1
Dumez, H.2
Judson, I.3
Wasag, B.4
Verweij, J.5
Brown, M.6
Dimitrijevic, S.7
Sciot, R.8
Stul, M.9
Vranck, H.10
Scurr, M.11
Hagemeijer, A.12
van Glabbeke, M.13
van Oosterom, A.T.14
-
27
-
-
0642368571
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
-
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-9.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4342-4349
-
-
Heinrich, M.C.1
Corless, C.L.2
Demetri, G.D.3
Blanke, C.D.4
von Mehren, M.5
Joensuu, H.6
McGreevey, L.S.7
Chen, C.J.8
Van den Abbeele, A.D.9
Druker, B.J.10
Kiese, B.11
Eisenberg, B.12
Roberts, P.J.13
Singer, S.14
Fletcher, C.D.15
Silberman, S.16
Dimitrijevic, S.17
Fletcher, J.A.18
-
28
-
-
20844460619
-
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
-
Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64:5913-9.
-
(2004)
Cancer Res
, vol.64
, pp. 5913-5919
-
-
Chen, L.L.1
Trent, J.C.2
Wu, E.F.3
Fuller, G.N.4
Ramdas, L.5
Zhang, W.6
Raymond, A.K.7
Prieto, V.G.8
Oyedeji, C.O.9
Hunt, K.K.10
Pollock, R.E.11
Feig, B.W.12
Hayes, K.J.13
Choi, H.14
Macapinlac, H.A.15
Hittelman, W.16
Velasco, M.A.17
Patel, S.18
Burgess, M.A.19
Benjamin, R.S.20
Frazier, M.L.21
more..
-
29
-
-
33847406095
-
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
-
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11:217-27.
-
(2007)
Cancer Cell
, vol.11
, pp. 217-227
-
-
Yun, C.H.1
Boggon, T.J.2
Li, Y.3
Woo, M.S.4
Greulich, H.5
Meyerson, M.6
Eck, M.J.7
-
30
-
-
33846187218
-
Update on epidermal growth factor receptor mutations in non-small cell lung cancer
-
Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12:7232-41.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7232-7241
-
-
Riely, G.J.1
Politi, K.A.2
Miller, V.A.3
Pao, W.4
-
31
-
-
3142691273
-
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
-
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004; 23:5387-93.
-
(2004)
Oncogene
, vol.23
, pp. 5387-5393
-
-
Berthou, S.1
Aebersold, D.M.2
Schmidt, L.S.3
Stroka, D.4
Heigl, C.5
Streit, B.6
Stalder, D.7
Gruber, G.8
Liang, C.9
Howlett, A.R.10
Candinas, D.11
Greiner, R.H.12
Lipson, K.E.13
Zimmer, Y.14
-
32
-
-
34249324494
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
-
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67:4408-17.
-
(2007)
Cancer Res
, vol.67
, pp. 4408-4417
-
-
Zou, H.Y.1
Li, Q.2
Lee, J.H.3
Arango, M.E.4
McDonnell, S.R.5
Yamazaki, S.6
Koudriakova, T.B.7
Alton, G.8
Cui, J.J.9
Kung, P.P.10
Nambu, M.D.11
Los, G.12
Bender, S.L.13
Mroczkowski, B.14
Christensen, J.G.15
-
33
-
-
44349120324
-
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma related mutations
-
Bellon SF, Kaplan Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma related mutations. J Biol Chem 2007.
-
(2007)
J Biol Chem
-
-
Bellon, S.F.1
Kaplan Lefko, P.2
Yang, Y.3
Zhang, Y.4
Moriguchi, J.5
Rex, K.6
Johnson, C.W.7
Rose, P.E.8
Long, A.M.9
O'Connor, A.B.10
Gu, Y.11
Coxon, A.12
Kim, T.S.13
Tasker, A.14
Burgess, T.L.15
Dussault, I.16
-
34
-
-
4644289313
-
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
-
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64:6652-9.
-
(2004)
Cancer Res
, vol.64
, pp. 6652-6659
-
-
Wood, E.R.1
Truesdale, A.T.2
McDonald, O.B.3
Yuan, D.4
Hassell, A.5
Dickerson, S.H.6
Ellis, B.7
Pennisi, C.8
Horne, E.9
Lackey, K.10
Alligood, K.J.11
Rusnak, D.W.12
Gilmer, T.M.13
Shewchuk, L.14
-
35
-
-
0037459344
-
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
-
Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112:831-43.
-
(2003)
Cell
, vol.112
, pp. 831-843
-
-
Azam, M.1
Latek, R.R.2
Daley, G.Q.3
-
36
-
-
4644240387
-
Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
-
Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, Marynen P, Gilliland DG. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64:6385-9.
-
(2004)
Cancer Res
, vol.64
, pp. 6385-6389
-
-
Cools, J.1
Mentens, N.2
Furet, P.3
Fabbro, D.4
Clark, J.J.5
Griffin, J.D.6
Marynen, P.7
Gilliland, D.G.8
-
37
-
-
34247506325
-
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
-
Ray A, Cowan Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109:5011-5.
-
(2007)
Blood
, vol.109
, pp. 5011-5015
-
-
Ray, A.1
Cowan Jacob, S.W.2
Manley, P.W.3
Mestan, J.4
Griffin, J.D.5
|